Live
BioPharma DiveCreate Medicines raises $122M to bolster in vivo CAR-T therapiesFierceBiotechBioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNSEndpoints NewsDrugmakers have to go through rigorous tests to get a lower tariff rateFierceBiotechBiopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?Promega BlogCharged Molecular Glues: The Molecular Trojan Horse That Slipped Past Biology’s Toughest BouncerClinical OMICsContact Lenses Show Promise for DepressionBioPharma DiveBiogen pushing tau drug forward despite Alzheimer’s study failureEndpoints NewsDegron, CREATE, TenNor raise capital; Cabaletta posts CAR-T dataEndpoints NewsAstraZeneca follows Merck with Phase 3 win in bladder cancerEndpoints NewsMacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attackFierceBiotechCreate Medicines fashions $122M fundraise for in vivo CAR-T dreamsBioPharma DiveWith new data, Regenxbio to seek FDA approval of Duchenne gene therapy
FierceBiotech Mar 30, 2026

Predicting Clinical Seizure Liability Earlier in Drug Development

Predicting Clinical Seizure Liability Earlier in Drug Development

Original
Body unavailable. Use the original source.